Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.

Lapostolle F, Van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators.

Am J Cardiovasc Drugs. 2018 Oct 23. doi: 10.1007/s40256-018-0305-0. [Epub ahead of print]

PMID:
30353444
2.

Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease-a review.

Alber HF, Huber K.

Wien Klin Wochenschr. 2018 Jul 20. doi: 10.1007/s00508-018-1357-5. [Epub ahead of print] Review.

PMID:
30030604
3.

Cohort profile: the Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography (CARDIIGAN) cohort.

Wanitschek M, Edlinger M, Dörler J, Alber HF.

BMJ Open. 2018 Jun 6;8(6):e021808. doi: 10.1136/bmjopen-2018-021808.

4.

An ordinal prediction model of the diagnosis of non-obstructive coronary artery and multi-vessel disease in the CARDIIGAN cohort.

Edlinger M, Dörler J, Ulmer H, Wanitschek M, Steyerberg EW, Alber HF, Van Calster B.

Int J Cardiol. 2018 Sep 15;267:8-12. doi: 10.1016/j.ijcard.2018.05.092. Epub 2018 May 24. No abstract available.

PMID:
29853277
5.

In-Hospital Outcome Comparing Bivalirudin to Heparin in Real-World Primary Percutaneous Coronary Intervention.

Hasun M, Dörler J, Edlinger M, Alber H, Von Lewinski D, Eber B, Roithinger FX, Berger R, Siostrzonek P, Grimm G, Benzer W, Wintersteller W, Huber K, Schuchlenz H, Weidinger F; Austrian Acute PCI Investigators.

Am J Cardiol. 2017 Dec 15;120(12):2135-2140. doi: 10.1016/j.amjcard.2017.08.037. Epub 2017 Sep 20.

PMID:
29103603
6.

Successful long-term management of spasticity in patients with multiple sclerosis using a software application (APP): A pilot study.

Ehling R, Edlinger M, Hermann K, Dröge K, Seidinger Y, Miller U, Alber HF, Brenneis C.

Mult Scler Relat Disord. 2017 Oct;17:15-21. doi: 10.1016/j.msard.2017.06.013. Epub 2017 Jun 27.

PMID:
29055449
8.

[Secondary prevention with antiplatelet therapy in cardiac rehabilitation].

Wanitschek MM, Alber HF.

Wien Med Wochenschr. 2018 Feb;168(1-2):16-22. doi: 10.1007/s10354-016-0539-x. Epub 2017 Jan 13. German.

PMID:
28091972
9.

Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.

Zbinden R, von Felten S, Wein B, Tueller D, Kurz DJ, Reho I, Galatius S, Alber H, Conen D, Pfisterer M, Kaiser C, Eberli FR.

Cardiovasc Ther. 2017 Feb;35(1):19-25. doi: 10.1111/1755-5922.12229.

PMID:
27662632
10.

Chronic Stable Angina.

Wanitschek MM, Dörler J, Alber HF.

N Engl J Med. 2016 Jul 21;375(3):292. doi: 10.1056/NEJMc1605394. No abstract available.

PMID:
27468080
11.

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.

Weiss TW, Aichinger J, Huber K, Speidl WS, Watzinger N, Zweiker R, Alber HF.

Wien Klin Wochenschr. 2016 Jun;128(11-12):450-7. doi: 10.1007/s00508-016-1016-7. Epub 2016 Jun 9. Review.

12.

Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.

Montalescot G, van 't Hof AW, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Collet JP, Goodman SG, Hammett CJ, Huber K, Janzon M, Lapostolle F, Lassen JF, Licour M, Merkely B, Salhi N, Silvain J, Storey RF, Ten Berg JM, Tsatsaris A, Zeymer U, Vicaut E, Hamm CW; ATLANTIC Investigators.

JACC Cardiovasc Interv. 2016 Apr 11;9(7):646-56. doi: 10.1016/j.jcin.2015.12.024. Epub 2016 Mar 5.

13.

Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: results from the BAsel Stent Kosten-Effektivitäts Trial PROspective Validation Examination randomized trial.

Kurz DJ, Bernheim AM, Tüller D, Zbinden R, Jeger R, Kaiser C, Galatius S, Hansen KW, Alber H, Pfisterer M, Eberli FR.

Am Heart J. 2015 Oct;170(4):787-795.e1. doi: 10.1016/j.ahj.2015.07.009. Epub 2015 Jul 17.

PMID:
26386803
14.

CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.

Klieber M, Oberacher H, Hofstaetter S, Beer B, Neururer M, Amann A, Alber H, Modak A.

J Pharmacol Exp Ther. 2015 Sep;354(3):426-30. doi: 10.1124/jpet.115.225680. Epub 2015 Jul 9.

15.

Distal renal artery stenosis after percutaneous renal denervation leading to renal impairment but normotension.

Koppelstaetter C, Kerschbaum J, Lenzhofer M, Glodny B, Esterhammer R, Frick M, Alber H, Mayer G.

J Clin Hypertens (Greenwich). 2015 Feb;17(2):162-4. doi: 10.1111/jch.12456. Epub 2014 Dec 24. No abstract available.

16.

Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.

Jeger RV, Pfisterer ME, Sørensen R, von Felten S, Alber H, Bonetti PO, Eberli F, Erne P, Pedrazzini G, Rickli H, Galatius S, Kaiser CA; BASKET and BASKET-PROVE investigators.

Am Heart J. 2014 Nov;168(5):698-705. doi: 10.1016/j.ahj.2014.07.019. Epub 2014 Jul 30.

PMID:
25440798
17.

Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.

Kaiser C, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz DJ, Pedrazzini G, Moccetti T, Rickli H, Weilenmann D, Vuillomenet A, Steiner M, Von Felten S, Vogt DR, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M; BASKET-PROVE II study group.

Circulation. 2015 Jan 6;131(1):74-81. doi: 10.1161/CIRCULATIONAHA.114.013520. Epub 2014 Nov 19.

PMID:
25411159
18.

Sex differences in independent factors associated with coronary artery disease.

Suessenbacher A, Wanitschek M, Dörler J, Neururer S, Frick M, Pachinger O, Alber HF.

Wien Klin Wochenschr. 2014 Nov;126(21-22):718-26. doi: 10.1007/s00508-014-0602-9. Epub 2014 Sep 13.

PMID:
25216757
19.

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators.

N Engl J Med. 2014 Sep 11;371(11):1016-27. doi: 10.1056/NEJMoa1407024. Epub 2014 Sep 1.

PMID:
25175921
20.

Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial.

Pedersen SH, Pfisterer M, Kaiser C, Jensen JS, Alber H, Rickenbacher P, Sørensen R, Iversen A, Jensen MT, Wadt K, Galatius S; BASKET-PROVE Investigators.

EuroIntervention. 2014 May;10(1):58-64. doi: 10.4244/EIJV10I1A11.

Supplemental Content

Loading ...
Support Center